Misplaced Pages

Atumelnant

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

Pharmaceutical compound
Atumelnant
Clinical data
Other namesCRN04894
Identifiers
IUPAC name
  • N-octan-3-yl]-6-(2-ethoxyphenyl)-3-piperazin-1-yl]pyridine-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC33H42F3N5O3
Molar mass613.726 g·mol
3D model (JSmol)
SMILES
  • CC1CN(CCN1C2=C(N=C(C=C2)C3=CC=CC=C3OCC)C(=O)N4CN5CCC4CC5)C(=O)C6(CCC6)C(F)(F)F
InChI
  • InChI=InChI=1S/C33H42F3N5O3/c1-3-23-20-40(31(43)32(14-7-15-32)33(34,35)36)18-19-41(23)27-11-10-25(24-8-5-6-9-28(24)44-4-2)37-29(27)30(42)38-26-21-39-16-12-22(26)13-17-39/h5-6,8-11,22-23,26H,3-4,7,12-21H2,1-2H3,(H,38,42)/t23-,26-/m1/s1
  • Key:QJRFBKYETDVAJQ-ZEQKJWHPSA-N

Atumelnant (CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders. It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands. Atumelnant is being evaluated to treat conditions such as congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome caused for example by pituitary adenomas.

References

  1. "Atumelnant (CRN04894)". crinetics.com. 14 August 2020.
  2. Varlamov EV, Gheorghiu ML, Fleseriu M (December 2024). "Pharmacological management of pituitary adenomas - what is new on the horizon?". Expert Opinion on Pharmacotherapy. doi:10.1080/14656566.2024.2446625. PMID 39718553.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: